Abbott Achieves CE Mark for Dual Glucose-Ketone Sensing Tech

Abbott has secured CE Mark approval for its innovative dual glucose-ketone sensing technology, Libre Duo. This marks a pioneering advance for diabetes care, combining continuous glucose and ketone monitoring in a single sensor. The Libre Duo systems offer real-time insights, crucial for diabetes management and the early detection of diabetic ketoacidosis (DKA), a severe diabetes complication.

Libre Duo aims to simplify diabetes care by integrating with the Libre digital health ecosystem, allowing data sharing with caregivers and healthcare providers. It supports automated insulin delivery systems, catering to varying age groups with different sensor durations.

The introduction of Libre Duo underscores the growing need for comprehensive diabetes care. DKA incidents are increasingly prevalent, outpacing hospitalizations for hypoglycemia, and continuous monitoring solutions like Libre Duo are vital for timely intervention and management.